Takeda sells $278M in non-core assets to Celltrion

Takeda Pharmaceutical Company has announced it will sell $278M in non-core assets to Celltrion.



“This announcement marks continued progress on our commitment to divest non-core products as we remain focused on maintaining our financial discipline and rapid deleveraging following our acquisition of Shire. One of several transactions since the launch of the divestment program, the sale announced today will further focus Takeda on our five key business areas and our pipeline of innovative medicines.”
Costa Saroukos, Chief Financial Officer, Takeda

The products in the divested portfolio consisted of OTC and prescription medicines sold in the Asia-Pacific region.

The_MergerSight_Group_Instagram
The_MergerSight_Group_LinkedIn
The_MergerSight_Group_Facebook

© 2018 - 2020 The MergerSight Group

Subscribe to Newsletter